GLG Network Survey: Antibody-Drug Conjugates

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

For this Network Survey, GLG surveyed 70 senior executives from pharmaceutical companies that manufacture ADCs across the US and Europe.

What will you learn from this survey?

  • Respondents commented on the development of Antibody Drug Conjugates (ADCs) including factors for selecting linkers and conjugation technologies, minimizing target effects of ADCs, and importance of pharmacokinetic and pharmacodynamic properties of ADCs.
  • The research also looked into the manufacturing of ADCs including current trend for insourcing vs outsourcing, important areas of expertise, and focus areas for successful commercialization.
  • Lastly, the survey captured the market overview covering aspects like areas where ADCs have long term potential, future outlook on the industry, challenges faced in IP protection and ADC targets seeing the most success.

Examples of findings:

  • Over half (53%) of respondents stated that efficacy and safety are the areas to focus for successful commercialisation.
  • Close to one-in-two (46%) experts agree that upcoming clinical readouts will have a positive impact on ADCs market in the next 2 years.
  • Over two-in-three (67%) experts reported that cleavable linker is the most significant advancement in payload technology.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Sanjeev Gangwar, former Vice President, Chemistry at Elie Pharmaceuticals.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • How are the recent developments in payload technology impacting the overall therapeutic index (efficacy and safety) of ADCs?
  • How important are the following pharmacokinetic properties of ADCs in optimizing dosing regimens and treatment outcomes?
  • Which of the following areas of expertise are the most important in ensuring quality, purity and stability throughout the manufacturing process of ADCs? Please rank the top 5, where rank 1 means the most important area of expertise.
  • For the successful commercialisation of ADCs, which of the following key considerations does your organisation focus on? Please rank the top 5, where rank 1 means the most important consideration.
  • In the pharma industry, what is the current trend for CDMO outsourcing vs in-house development for each of the following stages of ADC development?
  • Which of the following challenges does your organisation usually face in Intellectual Property (IP) protection for ADCs?
  • Companies like Astra Zeneca and Daiichi Sankyo recently announced building additional manufacturing facilities for ADCs. How likely is this capacity expansion trend in the industry to continue in the next 2 years?

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.